Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1 to 18 (canceled).

Claim 19 (currently amended). A ~~The~~ pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:





wherein

X is O or S;

Q is O or S;

n is an integer from 1 to 5;

~~R is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or~~

~~unsubstituted phenyl, substituted or unsubstituted terphenylyl, substituted or unsubstituted heteroaryl, and~~



~~wherein p is a number from 0 to 3;~~

~~m is a number from 0 to 4, and~~

~~n is a number from 0 to 5,~~

~~Z_1 and Z_2 are same or different and are independently selected from the group consisting of -O-, -S-, -N(R_5)-, -C(R_6)=C(R_7)-, -C(R_6)=N- and -N=C(R_6)- wherein R_5 is selected from H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl; R_6 and R_7 are H or R_6 and R_7 optionally may combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R_a and R_b groups;~~

~~Y is a bond or selected from the group consisting of -O-, -S-, -N(R_5)-, C_1-C_4 alkylene, (Z)- or (E)-ethylene, and cycloalkyl with 3 to 6 carbon atoms;~~

~~each R_a and each R_b are independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, ketoalkyl, hydroxyalkyl, aminoalkyl, -CH_2-NR_3R_4, alkoxy, aryloxy, arylalkyloxy, halo, haloalkyl, cyano, hydroxy, nitro, amino, -NR_3R_4, -SR_5, carboxamido, -$CONR_3R_4$, -O-carboxamido, -O-CO-NR_3R_4, sulfonamido, and -$SO_2NR_3R_4$, wherein R_3 and R_4 are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl and imino-methylamino and wherein optionally R_3 and R_4 together with the N atom to which they are attached to form a 5-7 membered cyclic ring; and~~

R_1 and R_2 are independently selected from the group consisting of H, substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen,~~ and optionally R_1 and R_2, may be taken together with the N atom to which they are attached to form a substituted or unsubstituted ring~~,

wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, unsubstituted carboxamido, $-CONR_3R_4$, $-NR_3R_4$, sulfonamido, $-SO_2NR_3R_4$, $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$,

wherein R_3 and R_4 are selected from the group consisting of hydrogen, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted saturated alkyl and unsubstituted saturated heteroalkyl;

or a ~~and~~ ~~the~~ pharmaceutically acceptable salt ~~salts~~ thereof.

Claim 20 (currently amended). The composition of claim 19, wherein X is O; Q is O; and n is 1. ~~and R is selected from the group consisting of substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, substituted or unsubstituted terphenylyl, and substituted or unsubstituted cis-stilbyl~~.

Claim 21 (currently amended). The composition of claim [[20]] 19, wherein X is O; Q is O and n is 1, 2 or 3. ~~R is substituted or unsubstituted biphenylyl.~~

Claim 22 (original). The composition of claim 21, wherein at least one of R_1 and R_2 is H.

Claim 23 (currently amended). The composition of claim 22, wherein R_1 is unsubstituted C_1-C_8 homoalkyl, C_1-C_8 heteroalkyl, or ~~C_1-C_8~~ C_3-C_8cycloalkyl.

Claim 24 (currently amended). The composition of claim [[23]] 22, wherein R_1 ~~the C_1-C_8 alkyl~~ is methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, or cycloheptenyl.

Claim 25 (original). The composition of claim 24, wherein R_1 is cyclohexyl.

Claim 26 (original). The composition of claim 19, wherein R_1 is a substituted or unsubstituted piperidinyl, furyl, furfuryl, furanyl, thiofuranyl, and morpholinyl.

Claim 27 (currently amended). The composition of claim 24, wherein ~~the compound is of the formula:~~ R_1 is fully saturated cyclohexyl.



~~and m is a number from 0 to 4 and n is a number from 0 to 5.~~

~~each R_a and each R_b is are independently selected from the group consisting of H, acyclo alkyl,alkenyl, alkynyl, cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, ketoalkyl, hydroxyalkyl, aminoalkyl, -CH_2-NR_3R_4, alkoxy, aryloxy, halo, haloalkyl, cyano, hydroxy, nitro, amino, -R_3R_4, carboxamido, ONR_3R_4, O-carboxamido, O-CO-NR_3R_4, sulfonamido, $SO_2NR_3R_4$; and~~

~~wherein R_3 and R_4 are independently selected from the group consisting of H,~~

~~alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl and imino-methylamino or R_3 and R_4 may combine to form a 5-7 membered cyclic ring.~~

Claim 28 (currently amended). The composition of claim [[10]] 27, wherein the compound is of the formula:



wherein Ra_1 and Ra_2 are independently selected from the group consisting of [[H]], unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, ~~aryl, substituted aryl, arylalkyl, substituted arylalkyl~~, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, ~~and~~ $-SO_2NR_3R_4$; $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$; ~~and~~

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; ~~or R_3 and R_4 may combine to form a 5-7 membered cyclic ring~~; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted alkyl, and unsubstituted heteroalkyl.

Claim 29 (currently amended). The composition of claim ~~28~~ 27, wherein ~~one of Ra_1 and Ra_2 is H.~~ the compound is of the formula:



or



wherein Ra_1 is selected from the group consisting of unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, $-SO_2NR_3R_4$, $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$;

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl.

Claim 30 (original). The composition of claim 29, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, or $-(CH_2)_2OH$.

Claim 31 (currently amended). The composition of claim [[30]]21, wherein~~Ra1 and Ra2 are each H.~~ each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, and $-SO_2NR_3R_4$ and

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted alkyl, and unsubstituted heteroalkyl.

Claim 32 (currently amended). The composition of claim 19, wherein the compound is ~~selected from the group consisting of n-butyl 4-benzyloxyphenyl carbamate and~~ N-cyclohexyl 3'-carboxamido biphenyl-3-yl carbamate~~and the pharmaceutically acceptable salt salts thereof~~.

Claim 33 (currently amended). The composition of claim 31, wherein R_1 is H and R_2 is C_3-C_8 cycloalkyl. ~~wherein the molecular weight of the R-X- group is greater than the molecular weight of the -NR_1R_2-group.~~

Claim 34 (currently amended). A method of inhibiting fatty acid amide hydrolase activity in a mammal, said method comprising administering to the mammal a compound of the formula:





wherein

X is O or S;

Q is O or S;

n is an integer from 1 to 5;

~~R is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl, substituted or unsubstituted terphenylyl, substituted or unsubstituted heteroaryl, and~~



~~wherein p is a number from 0 to 3;~~

~~m is a number from 0 to 4, and~~

~~n is a number from 0 to 5,~~

~~Z_1 and Z_2 are same or different and are independently selected from the group consisting of -O-, -S-, -N(R_5)-, -C(R_6)=C(R_7)-, -C(R_6)=N- and -N=C(R_6)- wherein R_5 is selected from H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl; R_6 and R_7 are H or R_6 and R_7 optionally may combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R_a and R_b groups;~~

~~Y is a bond or selected from the group consisting of -O-, -S-, -N(R_5)-, C_1-C_4 alkylene, (Z)- or (E)-ethylene, and cycloalkyl with 3 to 6 carbon atoms;~~

~~each R_a and each R_b are independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, ketoalkyl, hydroxyalkyl, aminoalkyl, -CH_2-NR_3R_4, alkoxy, aryloxy, arylalkyloxy, halo, haloalkyl, cyano, hydroxy, nitro, amino, -NR_3R_4, -SR_5, carboxamido, -$CONR_3R_4$, -O-carboxamido, -O-CO-NR_3R_4, sulfonamido, and -$SO_2NR_3R_4$, wherein R_3 and R_4 are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl and imino-methylamino and wherein optionally R_3 and R_4 together with the N atom to which they are attached to form a 5-7 membered cyclic ring; and~~

R_1 and R_2 are independently selected from the group consisting of H, substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen;~~, and optionally R_1 and R_2, may be taken together with the N atom to which they are attached to form a substituted or unsubstituted ring,~~

wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, unsubstituted carboxamido, $-CONR_3R_4$,$-NR_3R_4$, sulfonamido, $-SO_2NR_3R_4$, $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$,

wherein R_3 and R_4 are selected from the group consisting of hydrogen, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted saturated alkyl and unsubstituted saturated heteroalkyl;

or a ~~and~~ ~~the~~ pharmaceutically acceptable salt ~~salts~~ thereof.

Claim 35 (original). The method of claim 34, wherein the mammal is human.

Claim 36 (original). The method of claim 34, wherein the compound is administered orally.

Claim 37 (currently amended). The method of claim 34, wherein n is 1, 2, or 3, ~~R is substituted or unsubstituted biphenylyl,~~ R_2 is H, and R_1 is unsubstituted C_1-C_8 homoalkyl, unsubstituted C_1-C_8 heteroalkyl, or unsubstituted ~~C_1-C_8~~ C_3-C_8 cycloalkyl.

Claim 38 (currently amended). The method of claim [[37]] 34, wherein R_2 is hydrogen, and R_1 is fully saturated cyclohexyl. ~~the compound is of the formula:~~



~~and m is a number from 0 to 4 and n is a number from 0 to 5;~~

~~each R_a and each R_b are independently selected from the group consisting of H, acyclo alkyl, alkenyl, alkynyl, cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, ketoalkyl, hydroxyalkyl, aminoalkyl, -CH_2-NR_3R_4, alkoxy, aryloxy, halo, haloalkyl, cyano, hydroxy, nitro, amino, -R_3R_4, carboxamido, -ONR_3R_4, -O carboxamido, -O-CO-NR_3R_4, sulfonamido, -$SO_2NR_3R_4$; and~~

~~wherein R_3 and R_4 are independently selected from the group consisting of H, acyclo alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl and imino-methylamino or R_3 and R_4 may combine to form a 5-7 membered cyclic ring.~~

Claim 39 (new). The pharmaceutical composition of claim 21, wherein n is 1 or 2.

Claim 40 (new). The composition of claim 39, wherein the compound is of a formula selected from the group consisting of:



,



and



wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, unsubstituted carboxamido, $-CONR_3R_4$, $-NR_3R_4$, sulfonamido, $-SO_2NR_3R_4$, $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$,

wherein R_3 and R_4 are selected from the group consisting of hydrogen, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and optionally R_3 and R_4 may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, unsubstituted saturated alkyl and unsubstituted saturated heteroalkyl.

Claim 41 (new). The composition of claim 40, wherein R_2 is selected from the group consisting of substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, and optionally R_1 and R_2, may be taken together with the N atom to which they are attached to form a substituted or unsubstituted ring.

Claim 42 (new). The composition of claim 41 wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, SR_5, unsubstituted carboxamido, $-CONR_3R_4$, -sulfonamido, and $-SO_2NR_3R_4$.

Claim 43 (new). The composition of claim 42, wherein R_1 is hydrogen; and R_2 is an isomer of propyl, butyl, pentyl, hexyl, heptyl, octyl, heteroalkyl, cycloheteroalkyl, or at least partially saturated cycloalkyl.

Claim 44 (new). The composition of claim 43 wherein R_2 is at least partially saturated cycloalkyl or cycloheteroalkyl.

Claim 45 (new). The composition of claim 43 wherein the R_2 member is fully saturated and an isomer of pentyl, hexyl, heptyl, or octyl.

Claim 46 (new). The composition of claim 44, wherein the R_2 member is a fully saturated cycloalkyl.

Claim 47 (new). The composition of claim 41, wherein at least one of R_1 and R_2 is H.

Claim 48 (new). The composition of claim 44, wherein each Ra is independently selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, $-SO_2NH_2$, $-CH_2OH$, $-CF_3$, $-CH_2CH_3$, $-CH_3$, $n-C_3H_7$, $-NH_2$, F, $-NO_2$, -CN and -OH.

Claim 49 (new). The composition of claim 39, wherein the compound is of the formula:



Claim 50 (new). The composition of claim 49, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, $-SO_2NH_2$, $-CH_2OH$, – CF3, $-CH_3$, $-CH_2CH_3$, $n-C_3H_7$, $-NH_2$, -F, $-NO_2$, –CN, and -OH.

Claim 51 (new). The composition of claim 21, wherein there is at least one Ra member at the meta position.

Claim 52 (new). The composition of claim 21, wherein n is 2.

Claim 53 (new). The composition of claim 19, wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 54 (new). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:



wherein

X is O or S;
Q is O or S;
R is substituted or unsubstituted meta-biphenyl; and
R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 55 (new). The composition of claim 54, wherein X is O and Q is O and wherein R is unsubstituted meta biphenyl.

Claim 56 (new). The composition of claim 55, wherein one of R_1 and R_2 is hydrogen.

Claim 57 (new). The composition of claim 56, wherein R_1 is selected from the group consisting of unsubstituted at least partially saturated cycloalkyl and unsubstituted cycloheteroalkyl.

Claim 58 (new). The composition of claim 57, wherein R_1 is an at least partially saturated cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctyl, or cyclooctenyl.

Claim 59 (new). The composition of claim 56, wherein R_1 is a saturated cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

Claim 60 (new). The composition of claim 56, wherein R_1 is unsubstituted and is a saturated cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

Claim 61 (new). The method of claim 34, wherein the compound is N-cyclohexyl 3'-carboxamido biphenyl-3-yl carbamate.

Claim 62 (new). The method of claim 34, wherein n is 1, 2 or 3.

Claim 63 (new). The method of claim 62, wherein the compound is of a formula selected from the group consisting of:



,



and



wherein Ra_1 and Ra_2 are independently selected from the group consisting of unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, -CONR$_3$R$_4$, sulfonamido, -SO$_2$NR$_3$R$_4$; -C(O)R$_6$, -SR$_5$, -SO$_2$R$_6$, -S(O)R$_6$, -NR$_6$C(O)R$_7$, and -NR$_6$SO$_2$R$_7$;

wherein R$_3$ and R$_4$ are independently selected from the group consisting of H, unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino or R$_3$ and optionally R$_3$ and R$_4$ may be taken together with the N atom to which they are attached to form a 5-7 membered ring; and R$_5$, R$_6$ and R$_7$ are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl.

Claim 64 (new). The method of claim 63, wherein R$_2$ is independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl.

Claim 65 (new). A method of inhibiting fatty acid amide hydrolase in a mammal, said method comprising administering to the mammal a compound of the formula:



wherein

X is O or S;

Q is O or S;

R is a substituted or unsubstituted meta biphenyl;

R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 66 (new). The method of claim 65, wherein X is O and Q is O and the R_2 member is a fully saturated cycloalkyl.

Claim 67 (new). The method of claim 66, wherein at least one of R_1 and R_2 is H.

Claim 68 (new). The method of claim 67, wherein R is unsubstituted meta biphenyl.

Claim 69 (new). A compound of the formula:



wherein:

X is O or S;

Q is O or S;

n is 1, 2, or 3;

wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, -CH_2-NR_3R_4, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, -NR_3R_4, unsubstituted carboxamido, -$CONR_3R_4$, sulfonamido, -$SO_2NR_3R_4$; -$C(O)R_6$, -SR_5, -SO_2R_6, -$S(O)R_6$, -$NR_6C(O)R_7$, and -$NR_6SO_2R_7$;

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and wherein optionally R_3 and R_4 may together with the N atom to which they are attached combine to form a 5-7 membered ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl;

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen;

and the pharmaceutically acceptable salts thereof.

Claim 70 (new). The compound of claim 69, wherein the compound is of a formula selected from the group consisting of:





and



wherein Ra_1 and Ra_2 are independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, $-SO_2NR_3R_4$; $-C(O)R_6$, $-SR_5$, $-SO_2R_6$, $-S(O)R_6$, $-NR_6C(O)R_7$, and $-NR_6SO_2R_7$; and

wherein R_3 and R_4 are independently selected from the group consisting of H, unsubstituted saturated alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted hydroxyalkyl and imino-methylamino and wherein optionally R_3 and R_4 may together with the N atom to which they are attached combine to form a 5-7 membered cyclic ring; and R_5, R_6 and R_7 are independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl.

Claim 71 (new). The compound of claim 70, wherein R_2 is selected from the group consisting of substituted or unsubstituted straight or branched alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl.

Claim 72 (new). The compound of claim 71, wherein each Ra member is independently selected from the group consisting of unsubstituted saturated alkyl, unsubstituted heteroalkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted at least partially saturated cycloalkyl, unsubstituted ketoalkyl, unsubstituted hydroxyalkyl, unsubstituted aminoalkyl, $-CH_2-NR_3R_4$, unsubstituted alkoxy, halo, unsubstituted haloalkyl, cyano, hydroxy, nitro, amino, $-NR_3R_4$, $-SR_5$, unsubstituted carboxamido, $-CONR_3R_4$, sulfonamido, and $-SO_2NR_3R_4$.

Claim 73 (new). The compound of claim 72, wherein R_1 is hydrogen; and R_2 is an isomer of propyl, butyl, pentyl, hexyl, heptyl, octyl, heteroalkyl, cycloheteroalkyl, or at least partially saturated cycloalkyl.

Claim 74 (new). The compound of claim 70, wherein R_2 is selected from the group consisting of unsubstituted straight or branched alkyl, unsubstituted heteroalkyl, unsubstituted at least partially saturated cycloalkyl, and unsubstituted cycloheteroalkyl.

Claim 75 (new). The compound of claim 73, wherein R_2 is fully saturated and an isomer of pentyl, hexyl, heptyl, or octyl.

Claim 76 (new). The compound of claim 73, wherein the R_2 member is a fully saturated cycloalkyl.

Claim 77 (new). The compound of claim 70, wherein at least one of R_1 and R_2 is H.

Claim 78 (new). The compound of claim 74, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, SO_2NH_2, CH_2OH, $-CF_3$, $-CH_3$, $-CH_2CH_3$, $n-C_3H_7$, $-NH_2$, -F, $-NO_2$, -CN and -OH.

Claim 79 (new). The compound of claim 73, wherein the compound is of the formula:



Claim 80 (new). The compound of claim 79, wherein Ra_1 is selected from the group consisting of $-C(O)NH_2$, $-C(O)CH_3$, $-(CH_2)_2OH$, $-SO_2NH_2$, $-CH_2OH$, $-CF_3$, $-CH_3$, $-CH_2CH_3$, $n-C_3H_7$, $-NH_2$, -F, $-NO_2$, -CN and -OH.

Claim 81 (new). The compound of claim 79, wherein R_2 is selected from the group consisting of unsubstituted straight or branched alkyl, unsubstituted heteroalkyl, unsubstituted at least partially saturated cycloalkyl, and unsubstituted cycloheteroalkyl.

Claim 82 (new). The compound of claim 69, wherein n is 2.

Claim 83 (new). The compound of claim 69, wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 84 (new). A compound of the formula,



wherein

X is O or S;

Q is O or S;

R is substituted or unsubstituted meta-biphenyl;

R_1 and R_2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted at least partially saturated cycloalkyl, and substituted or unsubstituted cycloheteroalkyl, with the proviso that R_1 and R_2 are not both hydrogen.

Claim 85 (new). The compound of claim 84, wherein X is O and Q is O and R is unsubstituted meta biphenyl.

Claim 86 (new). The compound of claim 85, wherein one of R_1 and R_2 is hydrogen.

Claim 87 (new). The compound of claim 86, wherein R_1 is at least partially saturated unsubstituted C_3-C_8 cycloalkyl or unsubstituted C_3-C_8 cycloheteroalkyl.

Claim 88 (new). The compound of claim 86, wherein R_1 is an at least partially saturated cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctyl, or cyclooctenyl.

Claim 89 (new). The compound of claim 88, wherein R_1 is a saturated cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.

Claim 90 (new). The compound of claim 86, wherein R_1 is unsubstituted and is a saturated cyclopentyl, cyclohexyl, or cycloheptyl.

Claim 91 (new). The compound of claim 84, wherein the compound is N-cyclohexyl 3'-carboxamido biphenyl-3-yl carbamate.

Claim 92 (new). The compound of claim 83, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 1 micromolar.

Claim 93 (new). The compound of claim 83, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 10 nanomolar.

Claim 94 (new). The compound of claim 69, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 1 micromolar.

Claim 95 (new). The compound of claim 69, wherein the compound has an IC_{50} for inhibiting the human fatty acid amide hydrolase of less than 10 nanomolar.